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Summary 
The lysis of infected host cells by virus-specific cytolytic T lymphocytes (CTL) is an important 
factor in host resistance to viral infection. An optimal vaccine against human immunodeficiency 
virus type 1 (HIV-1) would elicit virus-specific CTL as well as neutralizing antibodies.  The induction 
by a vaccine of HIV-l-specific CD8 § CTL in humans has not been previously reported. In this 
study, CTL responses were evaluated in HIV-l-seronegative human volunteers participating  in 
a phase I acquired immune deficiency syndrome (AIDS) vaccine trial involving a novel vaccine 
regimen. Volunteers received an initial immunization with a live recombinant vaccinia virus vector 
carrying the HIV-1 env gene and a subsequent boost with purified env protein. An exceptionally 
strong env-specific CTL response was detected in one of two vaccine recipients,  while modest 
but  significant  env-specific  CTL  activity was present  in  the  second vaccinee.  Cloning  of the 
responding  CTL gave both CD4 + and CD8 + env-specific CTL clones, permitting  a detailed 
comparison of critical functional properties of these two types of CTL. In particular, the potential 
antiviral  effects of these CTL were evaluated in an in vitro system involving HIV-1 infection 
of cultures of normal autologous CD4 + lymphoblasts. At extremely low effector-to-target ratios, 
vaccine-induced CD8 + CTL clones lysed productively infected cells present within these cultures. 
When tested for lytic activity against target cells expressing the HIV-1 env gene, CD8 + CTL 
were 3-10-fold more active on a per cell basis than CD4 + CTL. However, when tested against 
autologous CD4 + lymphoblasts acutely infected with HIV-1, CD4 + clones lysed a much higher 
fraction  of the  target  cell  population  than  did  CD8 +  CTL.  CD4 +  CTL  were  shown  to 
recognize not only the infected cells within these acutely infected cultures but also noninfected 
CD4 + T  ceils  that  had passively taken up gp120 shed from infected cells  and/or free virions. 
These  results  were  confirmed  in  studies  in  which  CD4 +  lymphoblasts  were  exposed  to 
recombinant gp120 and used as targets for gp120-specific  CD4 + and CD8 + CTL clones,  gp120- 
pulsed,  noninfected targets were lysed in an antigen-specific fashion by CD4 § but not CD8 + 
CTL clones. Taken together, these observations demonstrate that in an in vitro HIV-1 infection, 
sufficient amounts  of gp120 antigen  are produced and shed by infected cells  to enable uptake 
by cells that are not yet infected, resulting in the lysis of these noninfected cells by gp120-specific, 
CD4 + CTL. However, the antigen processing pathways involved in this reaction do not allow 
for association of gp120 peptides with class I molecules on the target  cells.  Thus,  in contrast 
to  CD4 +  CTL,  gp120-specific  CD8 +  CTL  can  correctly  distinguish  between  productively 
infected cells and noninfected T  cells that  have acquired gp120 via CD4.  With respect to the 
critical question of crossreactivity of vaccine-induced CTL on divergent strains of HIV-1, some 
vaccine-induced CD8 + CTL clones showed complete crossreactivity with targets expressing the 
env genes  of the  divergent  MN  and  RF isolates.  The  implications  of these findings  for the 
development of HIV-1 vaccines and for the pathogenesis  of AIDS are discussed. 
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TL can control the spread of viral infections within the 
host by eradicating infected host cells (1-3). In the case 
of HIV-1 infection, a vigorous HIV-l-specific, CD8 + CTL 
response is detectable in the majority of seropositive individ- 
uals (4-7).  Activated CD8 + T  cells  from such individuals 
can suppress HIV-1 replication in vitro through direct lysis 
of infected cells and/or cytokine-mediated inhibition of viral 
replication (8-10). Although HIV-l-specific CD8 + CTL ul- 
timately fail to control HIV-1 infection in vivo, it is likely 
that the antiviral activity of these CTL helps to prolong the 
asymptomatic phase of infection  (11). 
In the vaccine setting, HIV-l-specific CTL induced by im- 
munization could potentially eliminate cells initially infected 
by  HIV-1  and  prevent  the  establishment  of disseminated 
chronic infection.  Thus,  there has been a great deal of in- 
terest in the design of vaccines capable of eliciting  HIV-1- 
specific CTL. Virus-specific CTL are typically derived from 
the  CD8 +  T  cell subset  and recognize processed peptide 
fragments of viral antigen in association with class I MHC 
gene products expressed on the surface of an infected cell (12, 
13). As a general rule,  the processing of a viral protein for 
association with class I MHC gene products and subsequent 
recognition by CD8 + CTL occurs only when the viral pro- 
tein is synthesized within the infected cell. In contrast, viral 
proteins taken up from the extracellular environment by an 
endocytic pathway are generally processed for assodation with 
class II MHC gene products and subsequent recognition by 
CD4 + T cells (14-17). It is therefore not surprising that im- 
munization of human volunteers with purified forms of the 
HIV-1 envelope protein precursor gp160 elicits a T  cell re- 
sponse that  consists exclusively of CD4 + T  cells.  Interest- 
ingly, in some gpl60 recipients, a majority of the responding 
env-specific  CD4 + T  cell clones have cytolytic activity (18). 
The  induction  by  a  vaccine  of a  CD8 +  CTL  response 
specific for HIV-1 has not been previously described in humans. 
Current notions about antigen processing suggest that the 
induction of such a response would require vaccination with 
live virus vectors such as recombinant vaccinia constructs car- 
rying HIV-1 genes (19, 20), or the use of other novel vaccine 
strategies that permit delivery of viral proteins to the cytoplasm 
of host cells (21-23).  In animal models, recombinant  vac- 
cinia virus vectors have been successfully used to elicit CTL 
responses against retroviral  antigens  (24-28). 
In a recent phase I vaccine trial, a small number of HIV-1- 
seronegative human volunteers were immunized with a live 
recombinant vaccinia virus vector carrying the HIV-1 env gene 
(vac-env) and boosted with purified recombinant gp160. This 
combined vaccine regimen is modeled after a similar vaccine 
strategy that has been effective in the simian immunodefidency 
virus system (29). With respect to the induction of CD8 + 
CTL, this combined regimen is of particular interest because 
of the potential  of vac-env  infection  to elicit  CD8 +  CTL 
specific for the HIV-1 envelope protein. In addition, env-specific 
CD4 § T cells activated by the initial vac-env immunization 
and/or by the gp160 boost may enhance the donal expansion 
of memory env-specific  CD8 + CTL  upon  subsequent ex- 
posure to HIV-l-infected cells. 
The  present  study  describes  CTL  responses  in  HIV-1- 
seronegative human volunteers immunized with this com- 
bined vac-env/gp160  vaccine regimen and provides the first 
demonstration  that  HIV-l-specific CD8 + CTL  can be in- 
duced in humans by candidate HIV-1 vaccines. The responding 
CTL were cloned,  and both CD4 + and CD8 + env-spedfic 
clones were obtained, permitting a detailed comparative anal- 
ysis of the interactions of these two different classes of CTL 
with  HIV-l-infected cells and with  noninfected  CD4 + T 
cells that have taken up free envelope protein via CD4. The 
results of these studies demonstrate the value of vaccine-induced 
CD8 + CTL in the destruction of infected cells, but heighten 
concern over the potential of CD4 + CTL to contribute to 
CD4 + T  cell depletion in vivo through  the destruction of 
noninfected cells. 
Materials  and Methods 
Vaccine Trial.  Vaccinia-naive  HIV-l-seronegative volunteers were 
immunized with candidate HIV-1 vaccines in a phase I vaccine trial 
organized by the NIAID AIDS Vaccine Clinical Trials Network. 
The vaccine regimen involved an initial immunization  with a live 
vac-env vector (HIVAC-le; Oncogen/Bristol-Myers Squibb, Seattle, 
WA), which carries the env gene of the reference LAI isolate of 
HIV-1. The preparation of this vector and initial studies of its safety 
and immunogenicity  have been presented in detail dsewhere (19, 
30, 31). The vac-env  vector was administered by standard intradermal 
scarification with bifurcated needle punctures. Some volunteers were 
immunized  with a control vaccinia vector lacking the HIV-1 env 
gene. 2 mo after immunization,  vac-enu recipients were boosted 
with 640/~g recombinant  HIV-1 (LAI) gp160 (VaxSyn; Micro- 
GeneSys, Inc., Meriden, CT). Previous studies have described the 
safety and immunogenicity  of recombinant  gp160 in HIV-l-sero- 
negative (32) and healthy HIV-l-seropositive (33) volunteers. The 
design of this combined vac-env/gp160 regimen and initial results 
of studies of the safety and immunogenicity  of this regimen are 
described in detail elsewhere (B. Graham et al., manuscript  sub- 
mitred for publication; P. Greenberg et al., manuscript submitted 
for publication). 
Antigens.  Purified recombinant HIV-1 (LAI) gp160 and gp120 
produced in the baculovirus expression system were obtained from 
MicroGeneSys, Inc. 
Constructs and Transfections.  Autologous EBV-transformed  B lym- 
phoblastoid cell lines (B-LCL)  1 from vaccinees and controls were 
transfected by electroporation  with an EBV-based eukaryotic ex- 
pression vector (34) carrying the HIV-1 env gene (pCEP4env). The 
plasmid pCEP4env was constructed by inserting into the multiple 
cloning site of pCEP4 (Invitrogen, San Diego, CA), the SalI-XhoI 
fragment of the plIIenv3-1  (35), a plasmid containing  the HIV-1 
(LAI) env gene. The pIUenv3-1 phsmid was obtained from the AIDS 
Research and Reference Reagent Program (Rockville, MD) (con- 
tributor,  Dr. Joseph Sodroski). In addition to the env coding se- 
quence, this fragment contains both exons of the rev gene, expres- 
sion of which is necessary for the production  ofenv protein in this 
system. In pCEP4env, both env and rev are under  the control of 
the constitutive cytomegalovirus immediate-early promoter. Each 
transfected B-LCL was placed into selective media containing  ap- 
propriate predetermined concentrations of hygromycin B for I>6 d 
before use in the in vitro stimulation  of env-specific  memory T 
cells. Expression of the HIV-1 env gene by transfectants was verified 
by indirect immunofluorescence using  the mAb 902. This  anti- 
1 Abbreviation used in this paper: B-LCL, B lymphoblastoid cell line. 
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(National Institutes of  Health), recognizes gp120 expressed on the 
surface of infected ceils (36). 
In Vitro Stimulation of env-specific CTL.  1 mo after the gp160 
boost, PBMC were isolated from vaccinees  and controls by discon- 
tinuous density gradient centrifugation and were stimulated in vitro 
with env-transfected  B-LCL. Stimulations were carried out by cul- 
turing PBMC with lethally irradiated (7,000 red), env-expressing 
autologous B-LCL in IL-2-free culture medium (CM) consisting 
of RPMI 1640, 10% FCS, 4 mM glutamine, 50 U/m1 penicillin, 
and 50 #g/ml streptomycin. On day 4 of the in vitro stimulation, 
the media was supplemented with 50 U/ml of IL-2. Cytolytic ac- 
tivity was measured 7-9 d after initiation  of the cultures. 
Functional Assays.  Cytotoxicity was measured in standard S1Cr- 
release assays at the indicated E/T ratios as previously described 
(37), except that the assay period was 8 h. Target cells were pulsed 
with the indicated recombinant antigens, or infected with HIV-1 
or recombinant vaccinia viruses, as described below, before labeling 
with SlCr and use in the cytolytic assay. The SEM of the percent 
specific lysis, determined as previously described (38), was almost 
always <5%. 
Vaccinia Vectors.  The use of vaccinia virus vectors for the ex- 
pression of the HIV-1 env gene has been described (19, 20). In the 
present study, the vectors vPE16 and vPE8, which contain the env 
gene of LAI isolate (BH8 clone) of HIV-1, were used. vPE16 car- 
ties the full-length env gene modified to remove vaccinia  virus tran- 
scription termination sequences (39). vPE8 carries a truncated form 
of the env gene with a stop codon at the end of the gp120 coding 
sequence (40). Vectors carrying the env genes of the RF and MN 
strains have been previously described (6). Control infections were 
carried out with the vaccinia vector vSC8, which lacks the HIV-1 
env gene, or with the standard wild-type WR vaccinia strain used 
in the preparation of vaccinia recombinants (41). Target cells were 
infected with recombinant vaccinia viruses at a multiplicity of in- 
fection of 10 for 12-18 h at 37~  before labeling with 5:Cr and 
use in cytolytic assays. Vaccinia  vectors used in this study were kindly 
provided by Drs. Pat Earl and Bernard Moss of the National Insti- 
tutes of Health and by the AIDS Research and Reference Reagent 
Bank. 
Isolation ofT Cell Clones.  On day 13 after a single in vitro stim- 
ulation with env-transfected autologous B-LCL, cultures with env- 
specific cytolytic activity were cloned by limiting  dilution  using 
PHA (0.25/~g/ml; Wellcome Diagnostics, Research Triangle Park, 
NC) and irradiated allogeneic PBMC as previously described (18). 
To assure a high (>95%) probability of monoclonality, cells were 
isolated only from plates seeded with doses of responding cells for 
which <10% of the wells were positive for growth. Clones were 
screened for HIV-1 env-specific cytolytic activity in SlCr-release 
assays with mock-infected, vSC8-infected, and vPE16-infected au- 
tologous  B-I.CL targets. All T cell clones and lines were main- 
tained in the presence of IL-2 and were restimulated every 7-10 d. 
For restimuhtion, clones were cultured in 24-well plates at 5  x 
10Vml with irradiated (5,000 tad) allogeneic PBMC and PHA. 
3 d after restimulation,  the media were replaced with fresh CM 
containing  Ib2 at 150 U/m1 for CD8 + clones or at 50 U/m1 for 
CD4 + clones. All clones were given two-part designations (e.g., 
A42.45), in which the first part indicates  the volunteer identification 
number and the second part indicates the individual clone from 
that volunteer. A single set of volunteer identification numbers is 
used in all publications describing results from HIV-1 vaccine trials 
organized by the NIAID AIDS Vaccine Clinical TriMs Network. 
HIV-1  Infections.  To generate  autologous  CD4 +  target  cell 
lines, PMBC from volunteers were stimulated with PHA and sub- 
sequently subjected to two cycles of cell sorting for CD4 expres- 
sion. The resulting polyclonal T cell lines were >99% CD4 +  . The 
lines were maintained by weekly restimulation in Ib2-containing 
medium with PHA and irradiated allogeneic PMBC as described 
above. The phenotype was checked biweekly and remained exclu- 
sively CD4 +. The CD4 + T cell lines were mock infected or in- 
fected with HIV-1 3 d after restimulation with PHA. Infections 
were carried out by resuspending the CD4 + T cells in cell-free su- 
pernatants of SupT1 cells infected 7 d previously with HIV-1 (LAI 
isolate) as previously described (18). After 4 h at 37~  CD4 + T 
cells were washed and then cultured in Ib2-containing media. In- 
fected cells were used as targets in SlCr-release assays 4-7 d after 
exposure to HIV-1. The percent of infected cells in these cultures 
was assessed by two different methods with comparable results. 
The first method involved staining of permeabilized cells for HIV-1 
gag antigen and has been previously described (18). The second 
method involved staining of the infected cell culture with an anti- 
CD4 mAb  (12T4D11; Coulter Immunology,  Hialeah, FL) that 
recognizes an epitope on CD4 that is spatially distinct from the 
gp120 binding site. Because  of  the complexing of CD4 with gp160 
in the endoplasmic  reticulum, cells  productively  infected  with HIV-1 
show a dramatic decrease in surface expression of CD4, and are 
readily distinguishable from noninfected cells that have taken up 
free gp120 via CD4 (42, 43). 
Results 
Analysis ~  CTL Responses in V~cine Recipients.  To evahate 
the  human  CTL  response  induced  by  the  vac-env/gp160 
regimen, an in vitro stimulation was used to activate and ex- 
pand env-specific memory T  cells in peripheral blood from 
vaccinees. Autologous B-LCL that had been transfected with 
the HW-1 env gene were lethally irradiated and used to stimu- 
late PBMC from vaccine recipients and controls. Like the 
macrophages and activated CD4 + T  cells that are produc- 
tively infected with HIV-1 in natural infection, B-LCL ex- 
press both class I and class II MHC molecules. Since the HIV-1 
envelope protein synthesized in infected cells is processed for 
association with both class I (4-7) and class II (18, 44) MHC 
molecules, these transfectants should stimulate env-specific 
memory  T  cells  from  both  the  CD8 +  and  the  CD4 + 
subsets.  Fig.  1 shows results of an indirect immunofluores- 
cence assay demonstrating surface expression of the HIV-1 
env protein by env-transfected B-LCL. Expression of the env 
gene was confirmed by immunoprecipitation of env protein 
(data not shown). 
9 d  after stimulation with env  transfectants, responding 
T cells were assayed for env-specific  cytolytic activity. As shown 
in Fig. 2 A, stimulated PBMC from vac-env/gp160 recipient 
no. A42 showed significant env-specific cytolytic activity that 
was 30-45% above the background level of vaccinia-specific 
cytolysis. Notably, this culture showed env-specific lytic ac- 
tivity even at low E/T ratios (0.1:1). Stimulated PBMC from 
a second vac-env/gp160 recipient (no. A52) also showed modest 
but significant env-specific CTL activity (Fig. 2 B). In con- 
trast,  a control vaccinee (no.  A41)  immunized with wild- 
type vaccinia did not have detectable env-specific CTL activity 
(Fig. 2 C). Stimulated PBMC from nonimmunized, HIV-1- 
seronegative volunteers (n  --  2) were also negative for env- 
specific CTL activity (Fig. 2 D). These results demonstrate 
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Figure 1.  Expression of the HIV-1 envelope protein by stimulator  cells 
used to activate memory CTL in vaccine recipients.  B-LCL were trans- 
fected with the HIV-1 env gene as described in Materials and Methods. 
Expression of envelope protein on env-transfected  (thick line) and control 
untransfected  (thin line) B-LCL was assessed by indirect  immunofluores- 
cence using the anti-gp120 mouse mAb 902. Background staining of trans- 
fected and untransfected  cells with an irrelevant  primary antibody was 
identical. 
that the vac-env/gp160 regimen can induce env-specific CTL 
in seronegative  humans. 
Cloning of env-specific CTL.  To characterize in a defini- 
tive fashion the env-specific  CTL induced by this vaccine 
regimen, limiting dilution cloning of the culture from volun- 
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Figure 3.  Specificity and phenotype of representative CTL clones from 
vac-env  recipient no. A42. Clones were assayed for cytolytic activity against 
autologous  B-I.CL that had been either mock infected (Mock),  infected 
with a control vaccinia vector (vSC8), or infected with a vac-env vector 
(vPE16).  The  phenotype  of each  CTL  clone,  as  determined  by  im- 
munofluorescence with anti-CD4 and anti-CD8 mouse mAbs, is indicated. 
Clones were tested at E/T ratios giving optimal lysis (1:1 for CD8 + CTL 
clones, and 30:1 for CD4 + CTL clones). 
Table  1.  MHC  Restriction  and Epitope  Specificity  of 
Vaccine-induced  CTL  Clones 
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Figure 2.  HIV-1  env-specific  cytolytic activity in stimulated cultures from 
vaccine recipients and controls. 9 d after initial in vitro stimulation of PBMC 
from vaccine recipients with autologous env-transfected  B-I.CL, responding 
cells were assayed for cytolytic activity against autologous B-LCL that had 
been either mock infected, infected with a control vaccinia virus vector 
(vSC8), or infected with a vac-env vector (vPE16). Effector cells were: (.4) 
stimulated  PBMC  from  the  vaccinia-naive,  HIV-l-seronegative  vac- 
env/gp160  recipient  no.  A42;  (B) stimulated  PBMC from the vaccinia- 
naive, HIV-l-seronegative vac-env/gp160 recipient no. A52; (C) stimulated 
PBMC from a vaccinia-naive, HIV-l-seronegative  volunteer (no. A41) im- 
munized with parental wild-type vaccinia; or (D) stimulated PBMC from 
a representative  nonimmune, HIV-l-seronegative  donor. 
MHC  Epitope 
Clone  restriction *  localization# 
A42.6  NTS  gp120 
A42.9  A3.1  gp 120 
A42.29  A3.1  gp120 
A42.34  NT  gp120 
A42.46  A3.1  gp120 
A42.52  B35  gp41 
A42.53  NT  gp120 
A52.161  A3.1  gp120 
* Clones were tested  for lytic activity against  control vaccinia-infected 
and vac-env-infected  target cells that were either MHC mismatched  or 
that shared a single class I allele with the donor. Donor genotypes were 
as follows. Donor no. A42: A3, All, B18, B35, Bw4, Bw6, Cw4, Cw5, 
DR3, DRw6(13), DQwl, DQw2; donor no. A52: A1, A3, BS, B35, 
Bw6, Cw4, DR1, DR5 (DRw12), DQwl, DQw3. For each clone tested, 
only targets  sharing the indicated allele were lysed in an antigen-specific 
fashion. 
* Epitopes recognized by env-specific CTL clones were localized to the 
gp120 or gp41 subunits  of the envelope protein using CTL assays with 
autologous B-LCL targets infected with the vaccinia vectors vPE16, which 
carries the fuU-length env gene, and vPE8, which carries a truncated form 
of the ear gene with a stop codon at the end of the gp120 coding se- 
quence.  See Materials  and Methods. 
s NT,  not tested. 
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tion of PBMC with env-transfected autologous B-LCL. Flow 
cytometric analysis  revealed  that >90%  of the responding 
T cells in this culture were CD8 +. The cloning was carried 
out under conditions that have been previously shown to 
permit efficient clonal expansion of all CD4 + and CD8 + 
human T cells (45) so that the clones obtained would reflect 
the composition of the culture at the time of cloning. Clones 
that grew out under these conditions were screened for env- 
specific cytolytic activity. Of the clones screened, a remark- 
able 36%  (20/56)  were specific for env antigen. Of these, 
10 clones grew well enough to permit detailed analysis  of 
their functional properties. The majority of the clones ob- 
tained were CD8 + and showed a high level of lytic activity 
against target cells expressing the HIV-1 env gene (Fig.  3). 
However, CD4 + CTL clones specific for the HIV-1 env pro- 
tein were also obtained.  Thus,  the vac-env/gp160  regimen 
induced env-specific CTL from both T cell subsets, env-spedfic 
CD8 + CTL were also cloned from vac-env/gp160  recipient 
no.  A52. 
Extensive previous  analysis  of env-specific  CD4 +  CTL 
cloned from HIV-1 vaccine recipients has shown that these 
CTL show classic MHC restriction (18, 37, 46). To deter- 
mine whether the CD8 + CTL described here were MHC 
restricted, vaccine-induced clones were tested for lytic activity 
against control vaccinia-infected and vac-env-infected  target 
cells that were either MHC mismatched or that shared a single 
class I allele with the donor (Table 1). These studies demon- 
strated that each of the CD8 + clones tested showed classic 
MHC restriction to a single self class I allele. In addition, 
B-LCL targets infected with recombinant vaccinia vectors car- 
rying wild-type or truncated forms of the HIV-1 env gene 
were used to determine whether these clones recognized epi- 
topes in the gp120 or gp41 subunits of the envelope protein. 
All of the clones were found to recognize epitopes in gp120, 
except for clone A42.52, which recognizes an epitope in gp41 
(Table  1). 
Comparative  Analysis  of the  Lyric  Activity of CD8 + and 
CD4 + CTL  Clones.  Because the HIV-1 envelope proteins 
are processed in infected cells for association with both class 
I and class II MHC gene products, it was possible to com- 
pare directly the lytic activity of vaccine-induced CD8 + and 
CD4 +  CTL  clones  against  the  the  same  env-expressing 
B-LCL targets. Lytic activity was compared on a per cell basis 
by testing clones against vac-env-infected targets over a wide 
range of E/T ratios at a constant and optimal assay time of 
8 h. Preliminary studies established that the kinetics of target 
cell lysis by both classes of CTL were similar (E. P. Miskovsky, 
P. E. Stanhope, W. Pavlat,  and R.  F. Siliciano,  manuscript 
in preparation). Results from a representative experiment are 
shown in Fig. 4.  Antigen-specific lysis was detected at ex- 
tremely  low  E/T  ratios  (0.03:1)  for  the  CD8 +  clone 
A42.46, while the CD4 § clone A42.45 was inactive at this 
ratio. On a per cell basis,  the CD8 + CTL clone was 3-10- 
fold more efficient than  the  CD4 +  clone.  Neither clone 
lysed mock-infected targets or target cells infected with con- 
trol vaccinia vectors at any E/T ratio.  Similar results were 
obtained  with  other  vaccine-induced CD4 +  and  CD8 + 
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Figure  4.  Comparative  analysis of cytolytic  activity of env-specific 
CD4 + and CD8 + CTL clones. Lytic activity of the representative env- 
specific CD4 + CTL clone A42.45  (thin  line) was compared with that of 
the representative env-specific  CD8 + CTL clone A42.46  (thick  line) over 
a wide range of E/T ratios. Target cells were autologous  B-LCL that had 
been either mock infected (x), or infected with a control vaccinia virus 
vector, vSC8 ([]),  or with the vac-env  vector, vPE16 (ll). 
CTL clones with different epitope specificities and MHC re- 
striction patterns, indicating that the more efficient lysis of 
target  cells  by CD8 +  CTL  is  a  general property of this 
subset of T  cells. 
Direct Lysis of HIV-l-infected Autologous  T  Cells by Vaccine- 
induced CD8 + CTL.  The results presented above indicate 
that vaccine-induced, env-specific  CD8 + CTL have a very 
high level of cytolytic activity against vac-env-infected B-LCL 
targets, while CD4 + CTL are somewhat less potent. How- 
ever, with respect to vaccine efficacy, the critical question is 
whether vaccine-induced CTL lyse autologous cells infected 
with HIV-1.  Analysis of this question is hampered by the 
difficulty in obtaining uniformly infected target cell popula- 
tions of the appropriate MHC genotype. For these studies, 
target cells were prepared by infecting an autologous PHA- 
induced polydonal CD4 + T  cell line with HIV-1  (LAI). 
4-7 d later, infected cultures were used as a source of target 
cells  in cytolytic assays with  CD8 +  CTL  clones.  At  this 
time, virus-induced cytopathic effects were generally not evi- 
dent in the infected cultures, although 20-30%  of the cells 
were productively infected as assessed by immunofluorescence. 
For two different vaccine-induced CD8 + CTL clones, the 
percent of the target cells lysed reached a plateau with in- 
creasing E/T ratios, the plateau being almost exactly equal 
to the percentage of productively infected cells within the 
culture as determined by immunofluorescence analysis (Fig. 
5). Plateau levels of lysis were reached at very low E/T ratios, 
indicating efficient antigen-specific lysis of HIV-l-infected au- 
tologous T  cells, consistent with the efficient lysis of vac- 
env-infected targets described above. Lysis of infected cells was 
observed for both the gp41-specific  CTL done A42.52 and 
gp120-specific  clone A42.53. Control mock-infected CD4 + 
T lymphoblasts were not lysed by either done. Taken together, 
these results demonstrate that vaccine-induced CD8 + CTL 
specific for the envelope protein can efficiently lyse HIV-1- 
infected autologous T  cells. 30  100- 
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Figure 5.  Lysis of HIV-l-infected, autologous CD4.  + T  ceils by vaccine- 
induced CD8 + CTL clones. The gp41-specific CD8 + CTL clone A42.52 
and the gp120-specific CD8 + CTL clone A42.53 were tested for lytic ac- 
tivity against  autologous  CD4 +  T  lymphoblasts  that had been either 
mock infected or infected with HIV-1 as described in Materials and Methods. 
For each experiment, the percent of the CD4 + lymphoblasts that were 
productively infected as assessed by immunofluorescence analysis is indi- 
cated by the dotted horizontal line. 
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Figure 6.  Autologous CD4 §  T  cells pulsed with gp120 are lysed by 
CD4 + but not CD8 + env-specific CTL clones. A  PHA-activated, autol- 
ogous CD4 § T  cell line was pulsed at 37~  overnight with media alone 
or with 30 #g/ml  of recombinant gp120 from the LAI isolate.  Pulsed 
CD4 + T  cells were then washed and labeled with 51Cr. Lysis by the in- 
dicated CD4 + and CD8 + CTL clones was measured in a standard SlCr- 
release assay at E/T ratios giving optimal lysis (1:1 for CD8 + CTL,  and 
30:1 for CD4 + CTL).  All of these clones with the exception of A42.52 
are specific for epitopes in gp120. 
CD4 + but Not CD8 + CTL Clones Mediate Lysis of Nonin- 
fected CD4 + T  Lymphoblasts Exposed to HIVI gpl20.  In the 
peripheral  lymphoid  organs  of HIV-l-infected individuals, 
noninfected  CD4 + T  cells  are exposed not only to HIV-1 
virions released by infected cells but also to free gp!20 released 
from infected cells and HIV-1 virions after the spontaneous 
dissociation of gp120-gp41 complexes (47, 48). Thus, while 
a fraction of the CD4 + cells present in the vicinity of an in- 
fected cell will become productively infected, other CD4 + 
T cells may simply bind gp120. Previous studies have shown 
that noninfected CD4 + lymphoblasts can take up free gp120 
via CD4 and process it for presentation with class II MHC 
gene products (18, 37, 49). More importantly,  these nonin- 
fected cells can then be lysed by gp120-specific CD4 + CTL 
in a reaction that may contribute to CD4 + T cell depletion 
in natural infection (18, 37). To determine whether CD8 § 
CTL  mediate  the  gp120-dependent  lysis  of  noninfected 
CD4 +  T  cells,  a  series  of vaccine-induced  CD8 §  CTL 
clones was tested for cytolytic activity against an autologous 
CD4 § T cell line that has been pulsed with media alone or 
with recombinant gp120 (Fig. 6). The gp120-pulsed targets 
cells  were  readily  lysed  by  three  different  gp120-specific 
CD4 + CTL clones (A42.5,  A42.32,  and A42.45).  In con- 
trast, there was only minimal lysis of the same gp120-pulsed 
targets by seven different CD8 § CTL clones from the same 
donor.  Neither  CD4 §  nor  CD8 +  clones  lysed  unpulsed 
target cells. These results establish that among the vaccine- 
induced gp120-specific CTL, CD4 + clones lyse noninfected 
CD4 + T  lymphoblasts  that  have  taken up soluble gp120, 
while CD8 §  clones are unable to do so. 
Lysis of Infected and Noninfected  CD4 +  T  Cells  in  an  In 
Vitro Model for HIVI Infection.  Additional experiments were 
carried out to confirm the results presented above within the 
context of an in vitro HIV-1 infection. CD4 + lymphoblasts 
were infected by exposure to supernatants from HIV-l-infected 
SupT1 cells. 4 d after infection, 10-30% of the cells showed 
evidence of productive infection by immunofluorescence anal- 
psi s. However, 100% of these target cells stained for gp120 
using an anti-gp120 mAb that detects endogenously synthe- 
sized gp120 as well as gp120 bound to CD4.  Lysis of this 
acutely infected target cell population by representative vaccine- 
induced CD4 + and CD8 + CTL clones was analyzed (Fig. 
7).  CD8 + CTL clones lysed a fraction of target cells equal 
to or slightly less than the number of productively infected 
cells in the culture as determined by immunofluorescence anal- 
ysis.  However,  gp120-specific  CD4 +  CTL  clones  consis- 
tently lysed a fraction of the target cells that was significantly 
higher than the fraction of productively infected cells within 
the culture. Although CD4 + CTL can lyse HIV-l-infected 
cells (18), these data indicate that at least some of the target 
cells killed by CD4 + CTL in this system were not produc- 
tively infected. This lysis was antigen specific since no lysis 
was observed in the absence of HIV-1 infection. The higher 
lytic activity of CD4 + CTL in this system is in sharp con- 
trast  to  the results  obtained in experiments  with  vac-env- 
infected target cells in which CD8 + CTL were much more 
efficient  on a per cell basis than CD4 + CTL (Fig.  4). In the 
in vitro HIV-1 infection, the observed lysis by CD4 § CTL 
of some cells that are not productively infected was consis- 
tent  with  flow cytometric evidence,  demonstrating  that  a 
sufficient amount of gp120 antigen is produced and shed by 
infected cells in the culture to give detectable surface staining 
by all of the target cells. These data are also consistent with 
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Figure 7.  Lytic activity of vaccine-induced  CD4 + and CD8 +  CTL 
against  an acutely  infected  autologous CD4 + T  cell line.  Autologous 
CD4 § lymphoblasts  were mock infected or were infected with HIV-1 by 
exposure to a cell-free supernatant  from HIV-l-infected SupT1 cells. 4-7 d 
later, mock-infected  and HIV-l-infected cultures  were used as a source of 
target cells for cytolytic assays with the gp120-specific CD4 + CTL done 
A42.45  (A and B) and the CD8 + CTL  clones A42.53  (.4) and A42.52 
(B). For each experiment, the percent  of the CD4 + lymphoblasts  that 
were productively  infected as assessed by immunofluorescence  analysis is 
indicated  by the arrow. 
the demonstration that  CD4 + lymphoblasts  pulsed  with 
recombinant gp120 are susceptible to lysis  by vaccine-induced 
CD4 + CTL but not by CD8 + CTL (Fig. 6). Thus, in con- 
trast to CD8 + CTL, CD4 + CTL specific for gp120 cannot 
correctly  distinguish between productively infected cells and 
noninfected cells that have acquired gp120 in an in vitro HIV-1 
infection. 
Crossreactivity  of  Vaccine,  induced  CD4 +  and  CD8 +  CTL 
Clones on Diverse Isolates Of  HIV-1.  Striking sequence diver- 
sity is observed among HIV-1 isolates from different individ- 
uals (50-55),  and to a lesser extent among sequential isolates 
and individual clones obtained from a given individual (56). 
A vaccine  that induces anti-HIV-1 responses  crossreactive  with 
a spectrum of possible HIV-1 variants would be the most 
beneficial. Therefore,  the crossreactivity of CTL clones in- 
duced by the vac-env/gp160  vaccine  regimen on diverse HIV-1 
isolates was assessed. Both the vac-env and the recombinant 
gp160 components of  this vaccine regimen  were derived from 
the reference LAI isolate of  HIV-1. Autologous B-LCL were 
infected with recombinant vaccinia virus vectors expressing 
env genes from LAI or divergent strains of HIV-1, and were 
Figure 8.  Effect of HIV-1 sequence variability on CTL recognition of 
the HIV-1 env protein.  The indicated  vaccine-induced CTL clones were 
tested for lyric activity against mock-infected autologous  B-LCL or autol- 
ogous B-LCL infected with the control vaccinia vector (vSCS), or with 
vaccinia vectors carrying the env genes of the reference LAI isohte (vPE16), 
the MN isolate (vMN-462),  or the RF isolate (vR.F-222). Clones were 
tested at E/T ratios giving optimal antigen-specific lysis (1:1 for CD8 + 
CTL, and  30:1 for CD4 + CTL). 
subsequently used as targets in a standard SlCr-release assay 
with vaccine-induced  CTL clones (Fig. 8). The gp120-specific 
CD4 + CTL clones A42.5, A42.32, and A42.45 all failed to 
recognize target cells expressing the env gene of the MN iso- 
late, which may  be more representative of  HIV-1 strains preva- 
lent in North America (57, 58). Clone A42.32 showed weak 
but consistent  crossreactivity with the more highly diver- 
gent RF env protein,  which was not recognized by clones 
A42.5 or A42.45. These results are consistent with previous 
studies, indicating that vaccine-induced CD4 + CTL clones 
specific for determinants in gp120 display little crossreactivity 
with divergent HIV-1 isolates (18, 37, 59). In contrast, greater 
crossreactivity  was  detected with  vaccine-induced  CD8 + 
CTL clones. Most importantly, several of the gp120-speeific 
CD8 + CTL clones recognized a highly conserved epitope, 
as evidenced by ef~cient lysis of cells expressing the env gene 
from the MN isolate and from the more highly divergent 
RF isolate. The epitope recognized by clone A42.46 is lo- 
cated in a highly conserved region at the NH2 terminus of 
gp120 (P. Johnson, S. A. Hammond, tL. F. Siliciano, and B. 
Walker, unpublished results). Interestingly, although the level 
of sequence variability in gp41 is considerably lower than that 
observed in the gp120 coding sequence, the gp41-specific 
CD8 + CTL clone A42.52 failed to recognize either the MN 
or RF  env  protein.  The gp120-specific CD8 + CTL clone 
A42.53 lysed cells expressing the env protein from the MN 
isolate, but not from the RF isolate. Taken together, these 
results demonstrate that this vaccine  regimen developed using 
the LAI isolate can induce CD8 + CTL that recognize di- 
verse isolates of HIV-1, including the representative North 
American isolate, MN, and, for some clones, even the more 
highly divergent RF isolate. 
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Studies  presented  here  demonstrate  that  CD8 +  CTL 
specific  for  HIV-1  can  be  induced  in  HIV-l-seronegative 
humans by vaccination. A novel vaccine protocol involving 
immunization with a live vac-env vector followed by boosting 
with recombinant envelope protein was used. The present 
study extends important observations in murine and primate 
systems showing that immunization with live recombinant 
vaccinia vectors carrying retroviral genes can induce retrovirus- 
specific  CD8 +  CTL  (24-28),  as  well  as  earlier work  in 
human volunteers showing that CD4 + CTL can be induced 
by immunization with  recombinant gp160  (18).  Cloning 
studies described here establish  definitively that both CD4 + 
and CD8 +  CTL  are induced by this vaccine regimen.  A 
detailed comparative analysis of the functional properties of 
these two types of env-specific  CTL has led to a number of 
conclusions that have implications for HIV-1 vaccine design 
and for AIDS pathogenesis. 
One particularly striking finding was that the env-specific 
CTL induced by the vac-env/gp160  regimen are extremely 
effective in lysing target cells expressing HIV-1 env antigen. 
CD8 +  CTL  cloned from a vac-env/gp160  recipient func- 
tioned impressively in vitro, lysing env-expressing target cells 
at exceedingly low E/T ratios (0.03:1).  This indicates that 
individual vaccine-induced CTL can readily lyse multiple target 
cells during the assay period. CD8 + CTL were several-fold 
more efficient on a per cell basis  than CD4 + CTL.  Even 
more remarkable was the fact that the culture from which 
these clones were derived demonstrated env-specific cytolytic 
activity at E/T ratios as low as 0.1:1 (Fig. 2 A). These assays 
were performed after a single in vitro stimulation. Thus, the 
extraordinary lyric activity observed in this culture did not 
result from selection by repeated in vitro stimulation. Rather, 
it reflects both the high lytic activity of individual env-specific 
CTL clones induced by this vaccine regimen and the high 
frequency of such clones in the culture. Because the cloning 
step was carried out using a nonspecific mitogen that effec- 
tively stimulates all T cells regardless of their phenotype or 
specificity (45),  the properties of resulting clones reflect the 
composition of the culture, that is of cells responding to the 
initial in vitro stimulation with env-transfected  stimulating 
cells. Of the clones isolated, a remarkable 36% were positive 
for enwspecific cytolytic activity. Most of these were CD8 § 
As is discussed below, it is likely that the high frequency of 
env-specific  CTL in this culture reflects not only the high 
frequency of memory env-specific CTL among PBMC from 
vaccinees, but also a rapid clonal expansion of these env-specific 
CTL in response to stimulating cells expressing env antigen. 
In any event, although only a small number of volunteers 
have been immunized with this vaccine regimen to date, the 
data presented here demonstrate that this approach can lead 
to  the generation of extremely vigorous  CD8 + CTL  re- 
sponses against cells expressing HIV-1 env antigen in at least 
some vaccinees. 
Another unique feature of the present study is that a com- 
bined live virus/purified protein vaccine regimen was used. 
Since vaccination of humans with purified recombinant forms 
of the HIV-1 envelope protein has been previously shown to 
induce a T cell response that is exclusively from the CD4 + 
subset (18, 60), it is likely that the induction of CD8 + CTL 
in these volunteers resulted from the initial vac-env immuni- 
zation.  CD4 + CTL specific for the env protein can be in- 
duced by immunization with either vac-env (P. E. Stanhope 
and K. F. Siliciano, unpublished observations) or with purified 
gp160 (18).  In addition to lysing infected cells,  many env- 
specific CD4 + T cells secrete ID2 and may thereby facilitate 
the clonal expansion of CD8 + CTL specific for the same an- 
tigen. In some systems, the generation of an effective CD8 + 
CTL  response upon viral challenge requires CD4 + T  cell 
help (61-64).  Because the HIV-1 envelope protein synthesized 
in infected cells is processed for association with both class 
I and class II MHC molecules (18,  44),  and because all of 
the cells that are productively infected in vivo express both 
class I and class II MHC molecules, infected cells should be 
capable  of  simultaneously  stimulating  both  CD8 §  and 
CD4 +  T  cells.  Since,  as  shown  here,  the  vac-env/gp160 
regimen induced both CD8 § and CD4 + env-specific T  cell 
clones, it is possible that the extremely intense CD8 + CTL 
response observed after in vitro stimulation with env-expressing 
stimulator cells was due in part to the ability of env-specific 
CD4 +  T  cells  to  promote  the  clonal  expansion  of env- 
specific CD8 § CTL.  If the same mechanism operates in vivo 
in  vaccinated individuals  who  are exposed to  HIV-1,  the 
resulting CD8 + CTL response may be of sufficient inten- 
sity to cause the rapid elimination of  productively infected cells. 
In addition to testing the lytic activity of vaccine-induced 
CTL clones against the standard vac-env-infected  targets, the 
interaction of env-specific  CD8 + CTL clones with HIV-1- 
infected autologous  CD4 +  T  cells  was  evaluated directly 
using an in vitro model of HIV-1.  The target cells in this 
model were autologous, nontransformed CD4 + T lympho- 
blasts.  Previous  in  vitro  studies  have  demonstrated  that 
CD8 + CTL isolated from HIV-l-infected individuals lysed 
HIV-l-infected macrophages and CD4 + T cells (3, 65),  and 
that CD4 + CTL induced by immunization of seronegative 
humans with gp160 could lyse autologous HIV-l-infected 
CD4 + lymphoblasts (18). The data presented here indicate 
that vaccine-induced CD8 + CTL efficiently lyse autologous 
HIV-l-infected cells. 
Data  presented here also  establish  that  vaccine-induced 
CD8 + CTL do not mediate the gp120-dependent lysis of 
noninfected CD4 + T  cells. As shown here and in previous 
studies (18, 37),  free gp120 can bind to CD4 on activated 
human CD4 + T cells and then be internalized and processed 
for presentation in association with MHC class II molecules, 
leading to lysis of the cells by gp120-specific  CD4 + CTL. 
However, the present study demonstrates that the same targets 
are not lysed by gp120-specific  CD8 + CTL from the same 
donor. This result is consistent with the notion that, with 
rare exceptions (66,  67), the processing pathway for exoge- 
nous antigen does not allow for association with MHC class 
I molecules (14-17).  These results were confirmed using an 
in vitro model of HIV-1 infection of activated autologous 
CD4 + T  cells. In cultures of acutely infected CD4 + lym- 
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the cells become productively infected, all of the cells stain 
with an anti-gpl20 antibody. This is the result of gpl20 re- 
lease from infected cells and/or HIV-1 virions, and subsequent 
CD4-dependent uptake by other cells (37). Most importantly, 
it  was  demonstrated  that  vaccine-induced gp120-specific 
CD4 + CTL lysed a fraction of target cells that was substan- 
tially greater than the fraction of productively infected cells, 
while CD8 + CTL lysed only the productively infected cells. 
In both cases, the lysis was antigen specific since no lysis was 
observed for targets that had not been initially exposed to 
HIV-1. The observed lysis of noninfected cells by gp120-specific 
CD4 + CTL does not represent the classic form of "inno- 
cent bystander killing" which involves the release by antigen- 
activated CTL of a stable diffusible mediator that can lyse 
other cells in a nonspecific fashion. In fact, vaccine-induced 
CD4 + CTL do not mediate this type of innocent bystander 
killing  and  instead  lyse  target  cells  in  a  highly  specific, 
contact-dependent fashion through a mechanism that is in- 
distinguishable from that used by the classic CD8 + CTL 
(E. P. Miskovsky, P. E. Stanhope, and R. F. Siliciano, manu- 
script in preparation). The lysis of noninfected cells observed 
in this system actually represents the gp120-specific  lysis of 
cells expressing processed gpl20 determinants in association 
with class II MHC molecules. Thus, gp120-specific  CD4 + 
CTL are unable to distinguish between infected cells  and 
noninfected CD4 + T cells that have simply taken up exog- 
enous gp120.  Because these observations were made in the 
context of an actual in vitro HIV-1 infection, they heighten 
concern over the possible role of gp120-specific CD4 + CTL 
in the process of CD4 + T cell depletion in infected individ- 
uals.  It is also important to note, however, that these data 
establish that gp120-specific CD8 + CTL do not mediate this 
potentially deleterious reaction. 
This study also addresses a major problem in HIV-1 vac- 
cine development: that of HIV-1 genomic heterogeneity. The 
ability of a vaccine to induce CTL crossreactive with a wide 
range of HIV-1 isolates  is of obvious importance. Even if a 
vaccine does not prevent initial infection, the presence of 
vaccine-induced CTL directed at conserved epitopes may alter 
the course of infection in a favorable way. Nowak et al. (68) 
recently proposed that there is an antigen diversity threshold 
below which the virus load can be controlled by the immune 
system but above which the virus load induces the imminent 
destruction of the immune system. A vaccine that sensitizes 
the immune system to a diverse set of isolates in effect raises 
the viral antigenic diversity threshold below which the virus 
population can be regulated. This is important in light of 
recent evidence for CTL escape variants in natural infection 
(69).  Thus,  it  is  encouraging  to  note  that  CD8 +  CTL 
clones active against divergent isolates of HIV-1 were readily 
detected among the small set of vaccine-induced clones ana- 
lyzed here. Crossreactive env-specific CD8 + CTL have also 
been detected in HIV-l-infected individuals (4, 6, 70). In these 
studies, screening was carried out using vac-env vectors de- 
veloped from the LAI isolate.  Therefore, only crossreactive 
CTL were detected, and it is unclear what fraction of the 
total env-specific CD8 + CTL response in natural infection 
consists of clones recognizing conserved epitopes. It is there- 
fore particularly promising that highly crossreactive CTL were 
readily detected in the vaccine setting without special screening. 
Of course, the crossreactivity of individual vaccine-induced 
CTL depends upon the epitope recognized and will there- 
fore vary with the MHC genotype of the vaccinee. 
Although the recruitment of vaccinia-naive,  seronegative 
volunteers represents a considerable challenge, the encouraging 
results of the present study and of studies of antibody and 
T cell proliferative responses in vac-env/gp160 recipients (B. 
Graham et al., manuscript submitted for publication;  P. Green- 
berg et al.,  manuscript submitted for publication) suggest 
that further trials of this type of vaccine regimen in large 
numbers of human volunteers should be carried out. 
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